Company intelligence / Profile preview

Telememory Holding

Kansas City, Kansas, United States

Ownership: Private
Development stage: Other

Overview

Telememory Holding acquired the assets and FDA Breakthrough Device designation of Dthera Sciences’ digital therapeutic for Alzheimer’s symptoms and is combining them with its own MoodSpark digital companion, a smart-display-based, AI-driven, non-pharmacological system to manage mood, loneliness and dementia symptoms in seniors; clinical work to date is limited to pilots and early clinical research inherited from Dthera, with no large pivotal trial results yet disclosed.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapyDigital therapeutic
Industry: Digital Health Medical Devices

Partnerships

Delmar Gardens Enterprises (pilot project at assisted-living facility to test MoodSpark digital companion)

Beyond the preview

Go deeper on Telememory Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telememory Holding.

Explore the full profile